New insights into how prostate cancer protects itself from latest therapies after researchers uncover the gene responsible for this resistance while investigating new drug that circumvents these protective mechanisms.

Medical Mythbusting Commentary for November 28, 2022


Drug triggers immune cells to attack prostate cancer

Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.